A new fish oil medication (omega-3 carboxylic acids [CA]) did not reduce the risk of cardiac events as compared to placebo in those patients with existing heart disease or who were at high risk of heart disease due to other medical conditions, according to results from the STRENGTH trial presented Sunday at the American Heart Association (AHA) Scientific Session 2020 virtual conference.